We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Antibody Tests Recommended for Parasitic Infection Diagnosis

By LabMedica International staff writers
Posted on 16 Jul 2019
Print article
Image: A photomicrograph of an unstained, formalin preserved stool specimen mount, revealed the presence of a Paragonimus westermani trematode egg. Human infections of this lung fluke are most common in eastern Asia and in South America (Photo courtesy of the CDC).
Image: A photomicrograph of an unstained, formalin preserved stool specimen mount, revealed the presence of a Paragonimus westermani trematode egg. Human infections of this lung fluke are most common in eastern Asia and in South America (Photo courtesy of the CDC).
Pleural parasitic infestation (PPI) is a disease prevalent in certain parts of the world and it is frequently misdiagnosed due to its lack of standardized diagnostic criteria. The clinical manifestations are non-specific and many patients are initially treated for tuberculosis or misdiagnosed as lung cancer.

Consumption of raw or undercooked fresh water crab, or crayfish infected with Paragonimus metacercariae is the main source of infection in human. Trichomonad parasites probably enter the respiratory tract following aspiration of oropharyngeal secretions. However, due to the expansion of worldwide food trading and increasing number of travelers and immigrants, the exposure history of the infection in each individual person is becoming more abstruse.

Scientists from Guangzhou Medical University (Guangzhou, China) retrospectively reviewed 11 patients admitted to the hospital due to respiratory symptoms and abnormal chest high-resolution computed tomography (HRCT) findings that revealed pleural effusion or pleural pulmonary involvement. All patients demonstrated respiratory symptoms, including shortness of breath, cough, fever, chest pain, excessive sputum and hemoptysis. A leukocytosis of greater than 10,000/μL and an eosinophilia greater than 500/μL of peripheral blood were present in 45.5% and 36.4% patients, respectively.

The enzyme-linked immunosorbent assay (ELISA) test for parasite-specific IgG antibodies was performed on serum from all patients and on pleural effusion from two patients. The parasite-specific IgG antibodies included the IgG antibodies of Taenia solium, Paragonimus westermani, and Spirometra spp., Clonorchis sinensis, Toxoplasma gondii and Echinococcus granulosus. Stool examinations for the detection of parasite eggs were performed in all patients.

The team reported that the mean concentrations of pleural effusion lactate dehydrogenase (LDH), adenosine deaminase (ADA), protein and carcinoembryonic antigen (CEA) were 338.2 U/L (range, 61–667 U/L), 11.6 U/L (range, 0.1–28.2 U/L), 43.7 g/dL (range, 21.9–88.1 g/dL), and 1.84 mg/mL (range, 0.28–4.8 mg/mL), respectively. The mean percentage of eosinophils in the pleural effusion was 19.5% (10.5–41%). Blood test was positive for parasite-specific IgG antibody in nine patients, including four for Paragonimus westermani, three for Taenia solium, one for Clonorchis sinensis and one for Echinococcus granulosus. Eggs of Clonorchis sinensis were detected in the stool of two patients. Sparganum was found in the pleural effusion of one patient. Respiratory symptoms and abnormal appearances in pulmonary radiographic examination were disappeared in all patients who received anti-parasitic treatment.

The authors concluded that in patients with unexplained pleural effusion, parasite-specific IgG antibody tests should be performed when pleural fluid testing shows eosinophilic pleural effusion. It is preferable to consider the diagnosis of PPI in clinical practice when serum parasite-specific IgG antibody test is positive. The study was published on July 4, 2019, in the journal BMC Infectious Diseases.

Related Links:
Guangzhou Medical University

New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Chagas Disease Test
LIAISON Chagas
New
Ultrasonic Cleaner
UC 300 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The advanced molecular test is designed to improve diagnosis of a genetic form of COPD (Photo courtesy of National Jewish Health)

Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD

Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more